Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
PainChek Ltd ( (AU:PCK) ) has shared an update.
PainChek Ltd reports positive progress in obtaining US FDA De Novo clearance for its entry into the US market, which could position it as the only regulatory-cleared product in the US long-term care market. The company has launched its Infant App on the Apple Store in Australia and continues to expand its global presence with over 100,000 contracted licenses and a high customer retention rate, indicating strong market adoption and potential for future growth.
More about PainChek Ltd
PainChek Ltd is a company that develops smart device-based pain assessment and monitoring applications. It primarily focuses on the healthcare industry, providing solutions for pain assessment in aged care, home care, and hospital segments. The company has a strong presence in Australia, the UK, New Zealand, and Canada, with a growing interest in the US market.
YTD Price Performance: 13.33%
Average Trading Volume: 1,109,716
Technical Sentiment Signal: Buy
Current Market Cap: A$62.63M
See more data about PCK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue